As CAR-T therapies mature, researchers begin to track long-term patient outcomes

CAR-T therapies progressed to market at an unprecedented pace. Due to their accelerated FDA approvals, long-term data on how patients fare post-treatment isn’t readily available. As the number of patients commercially treated with CAR-T therapy grows, long-term outcomes data has the potential to influence the entire industry of personalized cell and gene therapies. As with…